JPX · 4588.T
Oncolys BioPharma Inc.
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
Loading market information…
JPX · 7776.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
CellSeed Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CellSeed Inc.’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CellSeed Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
¥638-¥9 (-1.39%)
RaQualia Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.45% below the high.
¥4,975-¥10 (-0.2%)
Hoshi Iryo-Sanki Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.08% below the high.
¥749-¥17 (-2.22%)
CanBas Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 24.42% below the high.
¥122-¥4 (-3.17%)
ReproCELL Incorporated’s quoted price sits in the lower half of its reported 52-week range, 40.2% below the high.
$1.40-$0.07 (-4.76%)
MediciNova, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.1% below the high.
¥139-¥7 (-4.79%)
StemRIM’s quoted price sits in the lower half of its reported 52-week range, 62.23% below the high.
¥79-¥1 (-1.25%)
Nano Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.49% below the high.
